Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $140,000.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Mario Alberto Accardi sold 7,000 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $20.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider owned 205,566 shares of the company’s stock, valued at approximately $4,111,320. This represents a 3.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, July 29th, Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.23, for a total value of $126,744.06.
• On Tuesday, June 24th, Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $14.00, for a total value of $210,000.00.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $21.81 on Friday. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $23.24. The business has a 50 day moving average of $16.74 and a 200-day moving average of $14.63. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -12.18 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). On average, equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on CNTA. Wells Fargo & Company initiated coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 target price for the company. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $30.00 target price on the stock. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Friday, August 29th. They issued an “outperform” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.70.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares during the period. Exome Asset Management LLC lifted its position in Centessa Pharmaceuticals by 17.0% during the second quarter. Exome Asset Management LLC now owns 166,944 shares of the company’s stock worth $2,194,000 after purchasing an additional 24,200 shares during the period. Octagon Capital Advisors LP grew its stake in Centessa Pharmaceuticals by 24.8% during the second quarter. Octagon Capital Advisors LP now owns 1,030,000 shares of the company’s stock worth $13,534,000 after buying an additional 205,000 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after buying an additional 33,854 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $16,052,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.